Kala Pharmaceuticals Inc. Stock
Our community is currently high on Kala Pharmaceuticals Inc. with 4 Buy predictions and 0 Sell predictions.
With a target price of 28 € there is potential for a 44485.99% increase which would mean more than doubling the current price of 0.06 € for Kala Pharmaceuticals Inc..
Our community identified positive and negative aspects for Kala Pharmaceuticals Inc. stock for the coming years. 5 users see the criterium "Worthwhile Investment for the next years" as a plus for the Kala Pharmaceuticals Inc. stock. On the other hand our users think that "Unique positioning" could be a problem in the future.
Pros and Cons of Kala Pharmaceuticals Inc. in the next few years
Pros
?
M***** P*******
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Kala Pharmaceuticals Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Kala Pharmaceuticals Inc. | - | - | - | - | - | - | - |
| Evolus Inc | 2.620% | 5.140% | -10.131% | 4.419% | 0.587% | -38.404% | -43.485% |
| Heron Therapeutics Inc. | -2.600% | -2.739% | 12.453% | -73.548% | -62.388% | -72.792% | -95.833% |
| Rhythm Pharmaceuticals | -1.050% | 3.279% | -1.563% | 24.342% | 1.070% | 333.486% | 707.692% |
Comments
KALA BIO (NASDAQ:KALA) had its price target raised by analysts at HC Wainwright from $12.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for KALA provided by MarketBeat
KALA BIO (NASDAQ:KALA) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $15.00 to $33.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for KALA provided by MarketBeat
KALA BIO (NASDAQ:KALA) is now covered by analysts at Mizuho. They set an "outperform" rating and a $30.00 price target on the stock.
Show more
Ratings data for KALA provided by MarketBeat